Maxim Group assumed coverage on shares of Genprex (NASDAQ:GNPX) in a report released on Friday, September 14th, The Fly reports. The brokerage issued a buy rating and a $5.00 price target on the stock.
“We are initiating coverage of Buy rating and $5 price target. The company’s lead therapeutic candidate is Oncoprex, a novel gene-therapy- based approach for treating non-small cell lung cancer (NSCLC), a $15B market.”,” the firm’s analyst wrote.
Shares of NASDAQ GNPX traded up $0.07 during trading hours on Friday, reaching $2.03. 41,100 shares of the stock traded hands, compared to its average volume of 183,130. Genprex has a 52-week low of $2.00 and a 52-week high of $19.45.
Genprex Company Profile
Genprex, Inc, a clinical stage gene therapy company, develops drugs to treat cancer. Its lead product candidate is Oncoprex, an active anti-cancer agent that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC). It also conducts preclinical research for developing Oncoprex to be administered with immunotherapies in NSCLC; and research into other tumor suppressor genes associated with chromosome.
See Also: Find a Trading Strategy That Works
Receive News & Ratings for Genprex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genprex and related companies with MarketBeat.com's FREE daily email newsletter.